CYP2C8 & 3A4 inhibitors. Increased plasma conc w/ ciclosporin. Enhanced &/or prolonged hypoglycaemic effect w/ gemfibrozil, trimethoprim, rifampicin, ketoconazole, itraconazole, clarithromycin, ciclosporin, deferasirox, clopidogrel, other antidiabetics, MAOIs, non-selective β-blockers, ACE inhibitors, salicylates, NSAIDs, octreotide, alcohol, anabolic steroids. Reduced hypoglycaemic effect w/ OCs, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol, thyroid hormones, sympathomimetics.